TDT | Manama The Daily Tribune – www.newsofbahrain.com India's COVID-19 vaccine COVAXIN received an emergency use approval from the National Health Regulatory Authority (NHRA). COVAXIN, an inactivated SARS-CoV-2 antigen, will be available in Bahrain for those aged 18 years
TDT | Manama
The Daily Tribune – www.newsofbahrain.com
India’s COVID-19 vaccine COVAXIN received an emergency use approval from the National Health Regulatory Authority (NHRA).
COVAXIN, an inactivated SARS-CoV-2 antigen, will be available in Bahrain for those aged 18 years and above.
NHRA said its decision follows the careful evaluation carried out by the Clinical Trials Committee and Immunization Committee of data provided by the manufacturer, Bharath Biotech India.
The approval also follows the emergency use listing of COVAXIN by the World Health Organisation earlier this month.
The vaccine comes in single-dose vials and multidose vials of 5, 10 and 20 doses.
More than 26,000 people participated in the vaccine’s clinical trials, which established that the two-dose vaccine is 77.8% effective and 93.4% effective against severe cases of COVID-19.
